• Lassa Virus Spike: pH Changes and Inhibition

  2026-10-05

  Katz et al. map previously unresolved pH-dependent conformational changes in the Lassa virus spike, linking early transmembrane rearrangements with later receptor release and spike opening. Their structural and functional evidence also explains how ARN-75039 antagonizes viral entry, while defining important boundaries for interpreting these findings beyond the studied system.

• TUNEL and Mitochondrial Stress in Glioblastoma

  2026-10-05

  This overview examines how terminal deoxynucleotidyl transferase (TdT) labeling can contextualize apoptosis research in glioblastoma, using a recent study of mitochondrial CAT-tailing as the biological framework. It distinguishes reported findings from interpretation, explains conceptual applications in tissue sections and cultured cells, and evaluates the strengths and limits of TUNEL-based DNA fragmentation detection. The discussion also clarifies why TUNEL positivity is not, by itself, proof of apoptosis or evidence that mitochondrial CAT-tailing directly caused a phenotype.

• Maternal IL-17A and Neonatal GBS Risk

  2026-10-03

  A prospective Moroccan mother–newborn study identifies reduced maternal IL-17A, together with lower IL-1β and IL-4 responses, among GBS-colonized women whose newborns developed invasive disease. The work supports maternal IL-17A as a potential risk-stratification biomarker while showing how cytokine profiling and pathogen-recognition receptor stimulation can connect colonization status with neonatal outcomes.

• One-step TUNEL Cy3 Apoptosis Detection Kit Guide

  2026-10-02

  Connect DNA-fragment labeling with practical apoptosis readouts in tissue sections and cultured cells. This guide translates a hepatoprotective peptide study into a controlled workflow for spatial imaging, flow cytometry, and mechanistic validation.

• CUDC-907: Practical PI3K/HDAC Workflow

  2026-10-01

  CUDC-907 is a dual PI3K and HDAC inhibitor for controlled in vitro studies of PI3K/AKT signaling, histone acetylation, cell-cycle progression, and apoptosis. This guidance uses product-dossier specifications and laboratory workflow recommendations rather than directly matched paper evidence; the compound is for research use only and not for diagnostic, clinical, or therapeutic use.

• CD44 Metabolic Rewiring in IDH-Mutant Leukemia

  2026-09-30

  The reference study identifies CD44 as a metabolic dependency of IDH-mutant leukemia, linking R-2HG-driven signaling to pentose phosphate pathway activation and sustained NADPH production. Its findings support combined metabolic and IDH-directed experiments while clarifying how CD44 may contribute to incomplete responses and resistance.

• Oseltamivir acid: Neuraminidase Workflows

  2026-09-30

  Oseltamivir acid supports mechanism-first influenza antiviral research, from purified neuraminidase assays to infection and oncology cell models. This guide combines practical assay design with a cautious translational lesson from humanized-mouse prodrug research, helping teams separate direct enzyme inhibition from exposure and metabolism effects.

• ARCA Cy3 EGFP mRNA (5-moUTP): Lab Guide

  2026-09-29

  A scenario-based guide to using ARCA Cy3 EGFP mRNA (5-moUTP), SKU R1008, to separate mRNA delivery, translation, and cell-viability effects in mammalian cell assays. The article combines product specifications with practical controls and delivery-system context from recent mRNA research.

• GPX3–JNK/c-Jun Signaling in Pancreatic Cancer

  2026-09-29

  Ma et al. identify GPX3 as a pancreatic cancer suppressor that limits proliferation, motility, epithelial–mesenchymal transition, and resistance to Gemcitabine through inhibition of JNK/c-Jun signaling. The combination of database analysis, functional assays, and anisomycin rescue experiments provides a mechanistic framework for studying GPX3 as a determinant of chemotherapy response.

• Nystatin (Fungicidin): Assay Workflows

  2026-09-28

  Build more reproducible Candida susceptibility, adhesion, and membrane-integrity assays with Nystatin (Fungicidin). This guide also shows how the reference study’s negative nystatin result can improve controls when membrane-active compounds are evaluated in nonfungal cell-entry models.

• Moxidectin–Polyenes Synergy in Oral Candidiasis

  2026-09-28

  A 2024 study reports that moxidectin increases Candida albicans ergosterol levels and enhances the activity of the polyenes amphotericin B and nystatin. The findings connect a measurable change in fungal sterol biology to improved outcomes in a mouse model of oral candidiasis, while leaving clinical efficacy and broader species coverage to be tested.

• Moxidectin Potentiates Nystatin Against Oral Candidiasis

  2026-09-27

  A 2024 study reports that moxidectin increases Candida albicans ergosterol biosynthesis, strengthening the activity of the polyenes nystatin and amphotericin B in laboratory assays and a mouse oral-candidiasis model. The findings support a target-amplification strategy for polyene combinations, while leaving dose selection, safety, and clinical benefit to be established.

• Reading mRNA Delivery Beyond GFP: From Uptake to Function

  2026-09-26

  Dual-fluorescence mRNA reporters can help researchers distinguish cellular RNA-associated signal from productive protein expression. Learn how to interpret both readouts, build more informative delivery assays, and translate formulation-screening results with appropriate controls.

• AO/PI Staining Solution for Cell Viability Workflows

  2026-09-25

  AO/PI Staining Solution pairs two fluorescent DNA dyes to distinguish membrane-intact cells from cells with compromised membranes—an important complement to inflammation and apoptosis studies. Use it to strengthen high-glucose podocyte experiments with rapid fluorescent cell counting, while keeping pathway and apoptosis-specific assays in the workflow.

• HRP Rabbit Anti-Goat IgG (H+L) Antibody Workflow

  2026-09-25

  A practical guide to using this HRP-labeled secondary antibody for western blotting, ELISA, dot blots, and tissue-based assays when the primary antibody is raised in goat. It also shows how protein-detection workflows can support preclinical studies of localized p21 mRNA delivery—without confusing an assay reagent with a therapeutic intervention.

8637 records 1/576 page Next 12345 下5页 Last page